

ASX ANNOUNCEMENT

26 June 2020

RESPIRI EXECUTED AGREEMENT TO PARTNER WITH UK DATA RESEARCH CENTRE

Respiri Limited (ASX:RSH) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce that it has executed an agreement to partner with the University of Edinburgh in a new data research centre to help improve the lives of people living with respiratory conditions.

Known as BREATHE – Health Data Research Hub for Respiratory Health is led by the University of Edinburgh's Professor Aziz Sheikh, a primary care academic and epidemiologist with substantial research interests in asthma/allergy and in leveraging the potential of health information technology and data science to transform the delivery of care and improve population health. Professor Sheikh is a Director of the Usher Institute, the Asthma UK Centre for Applied Research (AUKCAR), the Scottish Allergy and Respiratory Academy (SARA), the NIHR Global Respiratory Health Unit (RESPIRE) and is Co-Director of the National Health Service (NHS) Digital Academy.

The centre will use data, such as that collected by the wheezo® ecosystem, for the development of innovations in the delivery of care for people with asthma, chronic obstructive pulmonary disease and respiratory infections.

BREATHE is one of seven new hubs led by Health Data Research UK (HDR UK) and part of a four-year £37 million investment from the Government Industrial Strategy Challenge Fund (ISCF) led by UK Research and Innovation.

Respiri will work with BREATHE to expand its patient experience program to the UK, as Respiri prepares to enter the European market in 2021, after the Company's Australian commercial launch in the fourth quarter calendar year 2020.

Commenting on the partnership, Respiri CEO and Managing Director, Mr Marjan Mikel said, "wheezo® brings cutting edge innovation in monitoring of respiratory disease and this is an incredible opportunity to demonstrate how the platform is beneficial to patients, the industry and the NHS. The timing is perfect for Respiri as we now have CE mark, clearing wheezo® for our European commercial launch in 2021. Our partner, Professor Sheikh and his team at the hub intend to be at the forefront of digitally-enabled respiratory health, and we are honoured to be a part of it."

The University of Edinburgh's partners at BREATHE are: Imperial College of Science Technology and Medicine, Nottingham University Hospitals NHS Trust, Swansea University, University of Leicester, Queen Mary University of London, Kings College London, Asthma UK, British Lung Foundation, NHS Waltham Forest Clinical Commissioning Group (on behalf of One London LHCRE), Greater London Authority, Respiri Ltd, StormID, Tiny Medical Apps, Novartis Pharmaceuticals UK, BreatheOx, GE Healthcare Finnamore Partners and Optimum Patient Care.

Read more about BREATHE

<https://www.hdruk.ac.uk/infrastructure/the-hubs/breathe/>

<https://youtu.be/URPK8TCTvPs>

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 26 June 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.